Get started
Author

Lars Møller Pedersen

Observed names: L M PEDERSEN, L M Pedersen, L Møller Pedersen, L. M. PEDERSEN, L. M. Pedersen, L. Møller Pedersen, L. Pedersen, L.M. Pedersen, LM Pedersen, Lars Møller Pedersen, Lars M Pedersen, Lars M. Pedersen, Lars M. Pedersen Peter G. Srensen, Lars Moeller Pedersen, Lars Moller Pedersen, Lars Möller Pedersen, Lars Möller Pedersen, Lars Pedersen, Møller Pedersen, Lars, Pedersen, LM, Pedersen, Lars M., Pedersen, Lars Moller, Pedersen, Lars Møller
Observed institutions: Roskilde University, University of Copenhagen, Uppsala University Hospital, The University of Texas MD Anderson Cancer Center, University of Southern Denmark, Lund University, Roskilde Sygehus, Sahlgrenska University Hospital, Frederiksberg Hospital, Odense University Hospital, Herlev Hospital, Bispebjerg Hospital, Hvidovre Hospital, Aarhus University Hospital, Copenhagen University Hospital, Gentofte Hospital, Rigshospitalet, Copenhagen Municipal Hospital, Karolinska Institutet, Zealand University Hospital, Vejle Sygehus, Nordic Lymphoma Group, Hospital South West Jutland, Zealand University Hospital Køge
ORCID: 0000-0002-9419-8841
Observed ORCID: 0000-0002-9419-8841
OpenAlex ID: A5010189385
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
2010 · Gilles Salles, John Francis Seymour, et al. · The Lancet · 1,079
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
2005 · Martin Hutchings, Annika Loft, et al. · Blood · 726
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
2012 · Tina Marie Green, Ken H. Young, et al. · Journal of Clinical Oncology · 686
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
2007 · Bertrand Coiffier, Stéphane Lepretre, et al. · Blood · 387
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
2019 · Emmanuel Bachy, John F. Seymour, et al. · Journal of Clinical Oncology · 291
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
2008 · Anton Hagenbeek, Ole Gadeberg, et al. · Blood · 264
Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
2006 · Martin Hutchings, Annika Loft, et al. · PubMed · 235
Prognostic significance of thrombocytosis in patients with primary lung cancer
1996 · LM Pedersen, N Milman · European Respiratory Journal · 232
PDF
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study
2014 · Anna Abrahamsson, Alexandra Albertsson-Lindblad, et al. · Blood · 136
Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma
2009 · Niels S. Andersen, Lone B. Pedersen, et al. · Journal of Clinical Oncology · 127
PDF
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
2012 · H. Holte, S. Leppä, et al. · Annals of Oncology · 117
PDF
Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy
2013 · Gilles Andre Salles, John Francis Seymour, et al. · Blood · 83
Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group
2013 · T. Wästerlid, P.N. Brown, et al. · Annals of Oncology · 77
R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group
2011 · A.O. Gang, C. Strøm, et al. · Annals of Oncology · 74
Microalbuminuria in patients with rheumatoid arthritis.
1995 · L.M. Pedersen, H Nordin, et al. · Annals of the Rheumatic Diseases · 73
PDF
FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas
2015 · P J Brown, K K Wong, et al. · Leukemia · 67
PDF
Reduced expression of TRIM 21/Ro52 predicts poor prognosis in diffuse large B‐cell lymphoma patients with and without rheumatic disease
2015 · S. Brauner, W. Zhou, et al. · Journal of Internal Medicine · 63
PDF
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
2012 · Myron S. Czuczman, Georg Hess, et al. · British Journal of Haematology · 58
PDF
Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.
2010 · G. A. Salles, J. F. Seymour, et al. · Journal of Clinical Oncology · 57
Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin’s lymphoma
2005 · Lars Møller Pedersen, Tobias Wirenfeldt Klausen, et al. · Annals of Hematology · 54
Diagnostic significance of platelet count and other blood analyses in patients with lung cancer
2003 · Lars Pedersen, Nils Milman · Oncology Reports · 52
Long term follow-up of the PRIMA study : half of patients receiving rituximab maintenance remain progression free at 10 years
2017 · Salles, Gilles Andre, Seymour, John Francis, et al. · Ghent University Academic Bibliography (Ghent University) · 47
TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma
2017 · Suet K Loo, Ewe S Ch'ng, et al. · Histopathology · 46
Increased Urinary Albumin Excretion Rate in Breast Cancer Patients
2000 · Lars M. Pedersen Peter G. Srensen · Acta Oncologica · 45
PDF
A population‐based study of prognosis in advanced stage follicular lymphoma managed by watch and wait
2015 · Tarec Christoffer El‐Galaly, Anders E. Bilgrau, et al. · British Journal of Haematology · 39
Works count: 159
Citation count: 5,982
H-index: 31
I10-index: 57
Year
Topic
Type